Beijing Sungen Biomedical Technology Co., Ltd
Clinical trials sponsored by Beijing Sungen Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection could save heart muscle after attack Results expected Apr 2027 (estimated)
-
New injection could save heart muscle after attack
Disease control Recruiting nowThis study tests a new medicine called SGC001 in people who have had a serious type of heart attack (anterior STEMI) and are scheduled for a procedure to open blocked arteries. The goal is to see if SGC001 can reduce the size of the heart damage and lower the chance of future hea…
Phase 2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
A multicenter, Dose-Escalation and expansion phase I/IIa clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy of SGT003 in patients with advanced solid tumors
Recruiting nowA Phase I/IIa clinical study SGT003 in patients with advanced solid tumors.
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
Last updated Sep 10, 2026 05:00 UTC